In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Genoptix, Novartis Continues Its Diagnostics Build-up

Executive Summary

Novartis' $440 million offer for cancer testing services lab Genoptix is another sign of the pharma giant's intent to build a full-blown molecular diagnostics business. The acquisition adds muscle to its existing Molecular Diagnostics unit. Coming just months after GE grabbed up Clarient, it is another example of the value of a specialty cancer services testing operation to an organization looking to bolster channel access to oncologists and pathologists.
Advertisement

Related Content

Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Delivering Cancer Diagnostics Tools
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011
What's Fueling The Recent Diagnostics Dealmaking?
GE Acquires Clarient To Anchor Its Molecular IVD Business
GE Acquires Clarient To Anchor Its Molecular IVD Business
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Does Roche Have It Right?
Novartis's Research Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel